PSMA PET/CT may beat Axumin for locating recurring prostate cancer, says study
> This Story

注册记数器 to rate this News Story
Forward Printable StoryPrint Comment




Molecular Imaging Homepage

First scan in US performed with uEXPLORER Total-Body PET/CT Can scan an entire patient within 15 to 30 seconds

FDG PET better for measuring Alzheimer's cognitive function than amyloid PET (FDG) PET measures brain glucose consumption

NNSA awards agreements to US firms for Mo-99 production Will produce with no highly-enriched uranium

Progenics collabs with VA on AI research for prostate cancer treatment Apply machine learning to medical images

ANSTO to hike nuclear medicine prices by as much as nine percent Follows Mo-99 leak

New bill calls for changing reimbursement for radiopharmaceuticals Aims for greater patient access to nuclear medicine exams

Bracco Imaging to acquire Blue Earth Diagnostics for $450 million Will gain rights over Axumin

Siemens showcases works in progress at SNMMI Includes TeamPlay, syngo Virtual Cockpit and a number of AI algorithms

First dual PET isotope scans performed on living organism Discussed at SNMMI 2019 Annual Meeting

MiE showcases cardiac PET scanner, Ancoris, at SNMMI Provides simultaneous 3D cardiac PET perfusion and CFR

Researchers at UCLA recommend
PSMA PET/CT over Axumin PET/CT
for locating recurring prostate

PSMA PET/CT may beat Axumin for locating recurring prostate cancer, says study

John R. Fischer , Staff Reporter
Researchers at UCLA are touting the use of a new imaging method for locating prostate cancer recurrence, compared to the conventional approach.

The team claims in a new study that in the investigational scanning approach, PSMA PET/CT, may offer a better chance of determining the location of recurring cancer following prostate cancer surgery than the current U.S. standard of fluciclovine positron emission tomography, known also as Axumin PET/CT.

Story Continues Below Advertisement

Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

"PSMA is an enzyme that is located on the cell surface of prostate cancer cells. The high number of PSMA molecules results in high amounts of ligands binding to this target," Dr. Johannes Czernin, professor of molecular and medical pharmacology at the David Geffen school of Medicine at UCLA, told HCB News. "There is very little PSMA expression in normal cells of the prostate and in other tissues. This is important for imaging because it results in a low background signal. Thus, the target (prostate cancer) to background ratio is very high. The advantage of this high target to background ratio is that relatively small lesions can be detected."

National Comprehensive Cancer Network guidelines call for using 18F-fluciclovine PET-CT for prostate cancer biochemical recurrence localization following radical prostatectomy, whereas European Association of Urology guidelines recommend prostate-specific membrane antigen (PSMA) PET-CT. Patients who undergo prostate cancer surgery must be routinely screened after for a recurrence of cancer. While recurring prostate cancer following surgery is usually in the area where the prostate was removed (prostate fossa), some cases have found cancer to be outside of it, in areas such as bones or lymph nodes.

By injecting patients with fluciclovine, physicians use PET/CT to track amino acids, which the contrast agent mimics due to their radioactive composition. As cancer cells consume more amino acids than regular cells, the technique helps locate the cancer by showing which cells consume more of the fluciclovine. The prostate-specific membrane antigen (PSMA) method uses the antigens’ protein expression levels to locate recurring cancer by tracking the cell surface proteins due to prostate cancer cells over-expressing a high level of PSMAs compared to normal ones.

Researchers tested both methods on 50 patients who previously underwent radical prostatectomy. Each participant had a biochemical recurrence of prostate cancer with low prostate-specific antigen levels, indicating that their cancer recurred at an early stage.
  Pages: 1 - 2 >>

Molecular Imaging Homepage

You Must Be Logged In To Post A Comment